clinical predictors and biomarkers in preeclampsia: …€¦ · annual meeting 2016 montreal, qc...

Canadian Society of Internal Medicine Annual Meeting 2016

Montreal, QC

CLINICAL PREDICTORS AND BIOMARKERS IN PREECLAMPSIA: WHAT

SHOULD WE TELL OUR PATIENTS?

Dr Evelyne Rey, Obstetric Medicine Division, CHU Sainte-Justine, University of Montreal

Montreal

1


Montreal, QC

Someofthedrugs,devices,ortreatmentmodalitiesmentionedinthispresentationare:aspirin

No Conflict Disclosures

E. Rey. CLINICAL PREDICTORS AND BIOMARKERS IN PREECLAMPSIA. 2016-10-29 2


Montreal, QC

The following presentation represents the views of the speakerat the time of the presentation. This information is meant for educational purposes, and should not replace other sources

of information or your medical judgment.

E. Rey. CLINICAL PREDICTORS AND BIOMARKERS IN PREECLAMPSIA. 2016-10-293

CSIM2016

OBJECTIVES

• Identifyspecificelementsfrompastmedicalhistory,physicalexaminationandobstetrichistorythatcanhelppredictpreeclampsia

• Selectpatientsthatcanbenefitfromimagingtechniquestohelppredictpreeclampsia

• Recognizetheclinicalutilityofexistingorpromisingbiomarkersforpredictionofpreeclampsia(PE)

4

CSIM2016

PLAN

• Physiology

• Predictors– Clinicalriskfactors

– Biomarkers

– Doppler

– Cell-freefetalDNA

– Podocyturia,Microalbuminuria

• Cases

5

CSIM2016

PartialmaternaltoleranceofallogenictrophoblastStage1

Stage2

ModifiedfromRedmanCW2005

6

CSIM2016 Adapted from Redman 20057

CSIM2016


Stage2

Stage3


Sub-clinicalinflammation,genetics,behavioralfactors

8

CSIM2016


Stage2

Stage3

Placentalmarkers


Sub-clinicalinflammation,genetics,Behavioralfactors

• ↓PP13• ↓PAPP-A• ↓ADAM12• ↓Metastin

• ↓β-hCG

• ↑Activin-A

• ↑Inhibin-A

9

CSIM2016


Stage2

Stage3

Vascularmarkers


AngiogenicF.

↓VEGF↓PlGF

AntiAngiogenicF.↑sFlt-1 ↑sEndoglin

↑sFlt-1/PlGF

10

CSIM2016


Stage2

Stage3

Imaging


11

CSIM2016


Stage2

Stage3


PredictionProphylaxisPreventoccurrencePreventseverity

EarlydiagnosisPrognosisClosematernalandfetalfollow-up

Severityprediction,Transfer,Delivery

12

CSIM2016

CLINICALRISKFACTORS

• Familyhistory

• Personalmedicalhistory

• Demographiccharacteristics

• Pregnancy-relatedfactors

13

CSIM2016

MageeLASOGC2008

14

CSIM2016 15

BartschE.BMJ2016

CSIM2016

CLINICALRISKFACTORS

PredictorModelsMetaanalysisAL-RubaieZTAetalBJOG2016

ParityPreviousPEEthnicitycHTConceptionmethodMeanBP

EPESensitivity70%Specificity70%

16

Poonetal.

17

BLOODPRESSURE

CSIM2016

UADOPPLERVELOCIMETRY1stT• Sensitivity48%,specificity92%• Notalone• NotdoneroutinelyinCanada

18

When?AnytimeifIUGR19-20w• Ifabnormalbiomarkers:usefulness?• IfriskofIUGR

LausmanA.JOGC2013

CSIM2016

BIOMARKERS

• Availability

• Aneuploidyscreening

– 1TPAPP-A

– 2T-hCG

–alphaFP–Estriol–Inhibin-A

19

CSIM2016

BIOMARKERS

1stT/earlysecondtrimester

– PAPP-A– Inhibin-A–PlGF

20

CSIM2016

Nicolaides2008

21

CSIM2016 22

EPE• Parity• PreviousPE• Ethnicity• cHT• Conception• MeanBP

LPE• +• FamilyHPE• Age• BMI

CSIM2016

OlivieraNetal.UltrasoundObstetGynecol2014

23

CSIM2016 24

CSIM2016

EFFICACYOFTHEMODELS?

• NoRCT

• ASPRE

• CohortscomparisonParksetal2015

25

CSIM2016

ParkFetal.UltrasundObstetGynecol2015;46:419

26

CSIM2016

Cell-freeFETALDNA• Increaseswithmarkersofplacentasize• Markerfortrophoblasticcelldeath• YuH2013:Increasesat11-14winEPE:sensitivity90%specificity85%

27

NEXTMARKER?

LevineRJAJOG2004

CSIM2016

Medicaldictionnonary2011

28

CSIM2016

MollerCCetal.JAmSocNephrol2009

29

SCMI2016 30

CSIM2016

Craicietal.Hypertension2013:1289-96

Lateentryinthestudy

PODOCYTURIA

31

SCMI2016

MICROALBUMINURIA< 20wks

– Lowrisk:no

– cHtorpreviousPreeclampsia

• higherlevel• Laura-Gonzalez2003:20mg/l

–Sensitivity79%etspecificity63%

–PPV46%NPV88%

32

CotéAMCurrentHypertensionreviews2010

CSIM2016

MICROALBUMINURIAINDB

• StrongriskfactorforPE• JensenDMDiabCare2010:846womenT1DB

–NoMicroA:12%PEvs

–MicroA:40%PE

–MicroA:ORa4,nulliparityORa3

•CastiglioniMTPregnancyHyper2014– cHTOR17(3-91),MicroAOR3.8(1.2-11.6),1TGHcOR2.8(1.1-7)

33

CSIM2016 34

CSIM2016

Case1

• Kimberly,29y,G1P0,

• Essentialchronichypertension

• Blackrace

• BMI36

• 154/104at12w

35

Riskofpreeclampsia?.5-10%.10-20%.20-30%.>30%

CSIM2016 36

BartschE.BMJ2016

BramhamK.BMJ2014

CSIM2016 38

CSIM2016 39

Abnormalif< 0.4MoM

CSIM2016

Case2

• Sandra,37y,G1,

• Type2DBx10y.Notsmoking

• Whiterace

• BMI44

• BP114/76at15w

40

Riskofpreeclampsia?

.5-10%

.10-20%

.20-30%

.>30%

SCMI2016

OTHERINFORMATION?

GH

41

Sandra=7.9%

Microalbuminuria

Sandra=none

CSIM2016

MICROALBUMINURIAINDB

• StrongriskfactorforPE• JensenDMDiabCare2010:846womenT1DB

–NoMicroA:12%PEvs

–MicroA:40%PE

–MicroA:ORa4,nulliparityORa3

• CastiglioniMTPregnancyHyper2014

– cHTOR17(3-91),MicroAOR3.8(1.2-11.6),1TGHcOR2.8(1.1-7)

42

CSIM2016 43

Abnormalif< 0.4MoM

CSIM2016

Case3

• Mandy,35y,G2P1

• PreviousEPE25w+IUGR.CS27w.

• Blackrace,BMI25

• BP130/80

44

Riskofpreeclampsia?

.10-20%

.20-30%

.30-40%

.>40%

CSIM2016

OTHERINFORMATION?

• Placenta• Recurrence• Vascularmalperfusionlesionsassociatedwithrecurrence

WeinerE.PrenatalDiagnosis2015

45

CSIM2016 46

Abnormalif< 0.4MoM

SCMI2016

Preeclampsiarisk?

Dany Suzy

Age 22 29

BMI 30.2 24.8

Race White Black

BP12sem 120/50 120/80

PAPP-A 0.34 1.72

47

HypothyroïdismNonsmokingG1NoFHofPrE

ClinicalF. 4.8% 6.9%

+MAPANDPAPP-A

2.1% 7.3%

SCMI2016

CONCLUSIONS

• HIGHRISKdefinedbyCLINICALFACTORS:REMAINMAJORTOOL

• Impactofbiomarkersonthisgroupofwomen?

• Biomarkersinmoderateriskwomenmoreuseful?

48

CSIM2016 49

HAVEALOOK!GEMOQ.CA

JOINUSATtheNASOM/GEMOQmeeting

CSIM2016 50

WithoutpreviousEPE

SCMI2016 51

BartschE.BMJ2016

clinical predictors and biomarkers in preeclampsia: …€¦ · annual meeting 2016 montreal, qc...

Documents